Strata Critical Medical, Inc. (SRTA) Revenue History
Annual and quarterly revenue from 2019 to present
SRTA Revenue Over Time (2019–2025)
SRTA Revenue Growth History
4 of 6 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- -24.9%
- FY2021 revenue growth
- +115.6%
- FY2022 revenue growth
- +189.2%
- FY2023 revenue growth
- +54.1%
- FY2024 revenue growth
- +10.4%
- FY2025 revenue growth
- -20.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $67.4M | +24.1% |
| Q4 2025 | $22.7M | -58.2% |
| Q3 2025 | $49.3M | -34.2% |
| Q2 2025 | $70.8M | +4.2% |
| Q1 2025 | $54.3M | +5.4% |
| Q4 2024 | $54.4M | +14.5% |
| Q3 2024 | $74.9M | +4.8% |
| Q2 2024 | $67.9M | +11.4% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
SRTA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SRTA Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 28, 2026, Strata Critical Medical, Inc. (SRTA) generated trailing twelve-month (TTM) revenue of $210.2 million, reflecting exceptional growth of +24.1% year-over-year. The most recent quarter (Q1 2026) recorded $67.4 million in revenue, up 196.4% sequentially.
Historical Growth Trajectory
SRTA's 5-year compound annual growth rate (CAGR) stands at +53.1%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +10.5% is below the 5-year average, signalling a growth deceleration in recent years. Strata Critical Medical, Inc.'s highest annual revenue of $248.7 million was recorded in 2024.
Revenue by Segment
SRTA's revenue is primarily driven by Logistics (90%), and Clinical (10%). With over half of revenue concentrated in Logistics, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Industrials sector peers — including ENSG (+19.2% YoY), ADUS (+19.6% YoY), and CCRN (-20.4% YoY) — SRTA has outperformed the peer group in revenue growth. Compare SRTA vs ENSG →
SRTA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SRTACurrent | $210M | +24.1% | +53.1% | -11.3% | |
 ENSG | $5.1B | +19.2% | +16.1% | 8.6% | |
 ADUS | $1.4B | +19.6% | +13.2% | 9.7% | |
 CCRN | $1.1B | -20.4% | +4.7% | -0.3% | |
 AMN | $2.7B | +19.9% | +2.7% | 1.2% | |
 TBI | $1.6B | -18.8% | -2.6% | -1.7% |
SRTA Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $197.1M | -20.7% | $41.1M | 20.9% | $-22,353,000 | -11.3% |
| 2024 | $248.7M | +10.4% | $58.9M | 23.7% | $-33,926,000 | -13.6% |
| 2023 | $225.2M | +54.1% | $42.1M | 18.7% | $-68,117,000 | -30.3% |
| 2022 | $146.1M | +189.2% | $22.3M | 15.2% | $-53,529,000 | -36.6% |
| 2021 | $50.5M | +115.6% | $10.5M | 20.8% | $-24,093,000 | -47.7% |
| 2020 | $23.4M | -24.9% | $2.3M | 9.9% | $-10,359,000 | -44.2% |
| 2019 | $31.2M | - | $4.7M | 15.1% | $-11,541,000 | -37.0% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SRTA — Frequently Asked Questions
Quick answers to the most common questions about buying SRTA stock.
Is SRTA's revenue growth accelerating or slowing?
SRTA revenue growth is accelerating. TTM revenue reached $210M, up +24.1% year-over-year — ahead of the 5-year CAGR of +53.1%. This indicates the business is expanding faster than its historical baseline.
What is SRTA's revenue history from 2019 to 2026?
Strata Critical Medical, Inc. (SRTA) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $210M, growing at +24.1% YoY. The 5-year CAGR is +53.1%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SRTA's long-term revenue growth rate (CAGR)?
Strata Critical Medical, Inc.'s 5-year revenue CAGR of +53.1% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +24.1% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SRTA.
Why does SRTA's quarterly revenue fluctuate?
SRTA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Strata Critical Medical, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is SRTA's revenue distributed by segment?
SRTA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SRTA's revenue compare to industry peers?
Strata Critical Medical, Inc. (SRTA) with TTM revenue of $210M and +24.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.